Market Closed -
Nasdaq
16:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
5.87
USD
|
-0.51%
|
|
+8.30%
|
-3.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
646.3
|
674.7
|
715.5
|
301.4
|
1,861
|
1,811
|
-
|
-
|
Enterprise Value (EV)
1 |
3,187
|
3,210
|
3,169
|
2,888
|
4,182
|
4,103
|
3,886
|
3,664
|
P/E ratio
|
-1.76
x
|
7.49
x
|
68.4
x
|
-2.31
x
|
-12.6
x
|
117
x
|
65.2
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.4
x
|
0.34
x
|
0.34
x
|
0.14
x
|
0.78
x
|
0.7
x
|
0.66
x
|
0.64
x
|
EV / Revenue
|
1.96
x
|
1.61
x
|
1.51
x
|
1.31
x
|
1.75
x
|
1.58
x
|
1.42
x
|
1.3
x
|
EV / EBITDA
|
8.96
x
|
7.04
x
|
5.89
x
|
5.62
x
|
7.49
x
|
6.86
x
|
6.28
x
|
5.76
x
|
EV / FCF
|
-70.1
x
|
9.95
x
|
16.3
x
|
155
x
|
13.8
x
|
13.8
x
|
12.7
x
|
9.96
x
|
FCF Yield
|
-1.43%
|
10%
|
6.12%
|
0.65%
|
7.23%
|
7.25%
|
7.85%
|
10%
|
Price to Book
|
6.22
x
|
4.52
x
|
4.01
x
|
2.02
x
|
54.1
x
|
3.83
x
|
2.6
x
|
1.94
x
|
Nbr of stocks (in thousands)
|
134,096
|
147,628
|
149,371
|
151,476
|
306,544
|
308,554
|
-
|
-
|
Reference price
2 |
4.820
|
4.570
|
4.790
|
1.990
|
6.070
|
5.870
|
5.870
|
5.870
|
Announcement Date
|
20-02-26
|
21-02-26
|
22-03-01
|
23-03-02
|
24-03-01
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,626
|
1,993
|
2,094
|
2,212
|
2,394
|
2,603
|
2,728
|
2,818
|
EBITDA
1 |
355.5
|
456.2
|
538.1
|
514.1
|
558.2
|
598.1
|
618.5
|
636.5
|
EBIT
1 |
292.2
|
325.6
|
387.9
|
343.3
|
379.1
|
521.1
|
533.6
|
543.6
|
Operating Margin
|
17.97%
|
16.34%
|
18.53%
|
15.52%
|
15.84%
|
20.02%
|
19.56%
|
19.29%
|
Earnings before Tax (EBT)
1 |
-220.2
|
-35.78
|
-
|
-
|
-40.72
|
46.74
|
89.25
|
-
|
Net income
1 |
-603.6
|
68.58
|
20.17
|
-
|
-83.99
|
14.44
|
22.71
|
18.4
|
Net margin
|
-37.11%
|
3.44%
|
0.96%
|
-
|
-3.51%
|
0.55%
|
0.83%
|
0.65%
|
EPS
2 |
-2.740
|
0.6100
|
0.0700
|
-0.8600
|
-0.4800
|
0.0500
|
0.0900
|
-
|
Free Cash Flow
1 |
-45.48
|
322.6
|
194.1
|
18.69
|
302.4
|
297.3
|
305.2
|
368
|
FCF margin
|
-2.8%
|
16.19%
|
9.27%
|
0.84%
|
12.63%
|
11.42%
|
11.19%
|
13.06%
|
FCF Conversion (EBITDA)
|
-
|
70.71%
|
36.07%
|
3.64%
|
54.17%
|
49.71%
|
49.34%
|
57.82%
|
FCF Conversion (Net income)
|
-
|
470.35%
|
962.28%
|
-
|
-
|
2,058.66%
|
1,343.62%
|
2,000%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-26
|
21-02-26
|
22-03-01
|
23-03-02
|
24-03-01
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
528.6
|
536.9
|
497.6
|
559.4
|
545.6
|
609.8
|
557.5
|
599
|
620
|
617
|
618.1
|
650.4
|
666.7
|
668.1
|
649.7
|
EBITDA
1 |
134.9
|
126.4
|
99.86
|
134.6
|
125.6
|
154
|
116.2
|
146.1
|
153.8
|
142.1
|
129.9
|
143.9
|
154.6
|
163.6
|
149.5
|
EBIT
1 |
116.4
|
77.96
|
81.31
|
119.4
|
106.8
|
105.3
|
128.7
|
124.3
|
131.9
|
92.98
|
108.6
|
131.1
|
140.2
|
141.1
|
106.5
|
Operating Margin
|
22.02%
|
14.52%
|
16.34%
|
21.35%
|
19.58%
|
17.27%
|
23.09%
|
20.76%
|
21.28%
|
15.07%
|
17.58%
|
20.16%
|
21.03%
|
21.12%
|
16.39%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
22.96
|
-83.46
|
-3.878
|
3.316
|
18.62
|
28.69
|
18.01
|
Net income
1 |
-4.237
|
-20.46
|
-2.156
|
-120.8
|
-
|
-
|
-
|
-
|
9.682
|
-98.65
|
-1.21
|
1.034
|
5.809
|
8.951
|
5.655
|
Net margin
|
-0.8%
|
-3.81%
|
-0.43%
|
-21.6%
|
-
|
-
|
-
|
-
|
1.56%
|
-15.99%
|
-0.2%
|
0.16%
|
0.87%
|
1.34%
|
0.87%
|
EPS
2 |
-0.0300
|
-0.0400
|
-0.0100
|
-0.8000
|
-0.0200
|
-0.0300
|
-0.0500
|
0.0800
|
0.0600
|
-0.4000
|
-
|
-
|
0.0200
|
0.0300
|
0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-03
|
22-03-01
|
22-05-04
|
22-08-05
|
22-11-04
|
23-03-02
|
23-05-05
|
23-08-04
|
23-11-07
|
24-03-01
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
2,541
|
2,536
|
2,454
|
2,587
|
2,321
|
2,292
|
2,074
|
1,852
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
7.147
x
|
5.559
x
|
4.561
x
|
5.031
x
|
4.158
x
|
3.832
x
|
3.354
x
|
2.91
x
|
Free Cash Flow
1 |
-45.5
|
323
|
194
|
18.7
|
302
|
297
|
305
|
368
|
ROE (net income / shareholders' equity)
|
28.1%
|
71.4%
|
75.5%
|
75.4%
|
194%
|
34.3%
|
26.4%
|
21.3%
|
ROA (Net income/ Total Assets)
|
2.58%
|
4.98%
|
6.5%
|
5.37%
|
5.43%
|
4.57%
|
4.67%
|
4.77%
|
Assets
1 |
-23,360
|
1,377
|
310.5
|
-
|
-1,546
|
315.9
|
486.3
|
386
|
Book Value Per Share
2 |
0.7800
|
1.010
|
1.200
|
0.9800
|
0.1100
|
1.530
|
2.260
|
3.020
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
47.2
|
56.4
|
47.7
|
46.4
|
43.2
|
59.1
|
61.9
|
58.2
|
Capex / Sales
|
2.9%
|
2.83%
|
2.28%
|
2.1%
|
1.81%
|
2.27%
|
2.27%
|
2.06%
|
Announcement Date
|
20-02-26
|
21-02-26
|
22-03-01
|
23-03-02
|
24-03-01
|
-
|
-
|
-
|
Last Close Price
5.87
USD Average target price
7.312
USD Spread / Average Target +24.57% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.29% | 1.81B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|